Hims & Hers Health ( HIMS -7.38%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Additionally, the FDA last week hindered the ability of compounded drugmakers, including HIMS, to sell lower-cost versions of semaglutide, the weight-loss drug that has proliferated widely.

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s expectations, but shares fell hard in after-hours trading, in an ...

Hims' GLP-1 drugs start at $199 a month, while Wegovy and Ozempic cost over $900 a month — though the price many patients pay depends on their insurance. Earlier this month, Hims ran a Super ...

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company ...

If you want to buy and hold Hims & Hers, consider dollar-cost averaging, and monitoring its future growth outside of compounded GLP-1 agonists. Before you buy stock in Hims & Hers Health ...

Hims & Hers offers a range of prescriptions through asynchronous telehealth services, including for weight loss, anxiety, libido, hair loss and skincare. Hims & Hers reported a nearly $1.5 billion ...

More data on each subscriber which will feed into HIMS LLM MedMatch to increase personalization even more. Aside from cost and convenience, personalization is the key reason why HIMS has a ...